» Articles » PMID: 24943904

Ab Interno Approach to the Subconjunctival Space Using a Collagen Glaucoma Stent

Overview
Specialty Ophthalmology
Date 2014 Jun 20
PMID 24943904
Citations 101
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: This review considers a minimally invasive ab interno approach to glaucoma filtration surgery. Glaucoma filtration surgery can be defined as an attempt to lower intraocular pressure (IOP) by the surgical formation of an artificial drainage pathway from the anterior chamber to the subconjunctival space. Subconjunctival drainage of aqueous fluid has been a cornerstone of glaucoma surgery for more than a century. Varying techniques have been deployed to provide access to this space. Yet, despite numerous innovations in filtering surgery to achieve safe IOP reduction, too many short-term and long-term complications are associated with this surgery. This article describes the development of a new, soft, and permanent ab interno collagen implant (XEN gel stent) to optimize aqueous drainage to the subconjunctival space. Specific characteristics are critical in designing such an implant. Determining the optimum size of the device lumen to avoid hypotony while maximizing long-term outflow is crucial. Other topics discussed include material, length, diameter, flexibility, stability, and biocompatibility of the implant. Preclinical and human eye testing shows that the implant does not seem to occlude inside the lumen and the implant material does not appear to cause tissue reaction in the eye. The ab interno placement of the stent offers an alternative for lowering IOP with a minimally invasive procedure, minimum conjunctival tissue disruption, restricted flow to avoid hypotony, and long-term safety.

Financial Disclosure: Dr. Lewis received financial support from Aquesys, Inc. as a consultant.

Citing Articles

Update on Surgical Techniques Best Practices to Optimize Outcomes Following Gel Stent Implantation.

Vera V, Sheybani A, Panarelli J, Grover D, Lee J, Craven E Clin Ophthalmol. 2025; 19:325-347.

PMID: 39911142 PMC: 11794994. DOI: 10.2147/OPTH.S487718.


Xen 63 versus Preserflo MicroShunt implant in patients with primary open-angle glaucoma.

Martinez-de-la-Casa J, Pascual-Santiago A, Morales-Fernandez L, Saez-Frances F, Garcia-Saenz S, Guemes-Villahoz N Sci Rep. 2025; 15(1):1634.

PMID: 39794378 PMC: 11723952. DOI: 10.1038/s41598-024-81616-3.


Results of XEN45 Gel Stent Implantation in the Treatment of Primary Open-Angle Glaucoma Using 5, 10 or 20 g Mitomycin C: A Pilot Study.

Reichel F, Guggenberger V, Faber H, Neubauer J, Voykov B J Ophthalmol. 2024; 2024:3895054.

PMID: 39492955 PMC: 11531357. DOI: 10.1155/2024/3895054.


XEN Gel Stent Failure Due to Luminal Obstruction.

Amarasekera D, A Shankar V, Razeghinejad R J Ophthalmic Vis Res. 2024; 19(3):386-391.

PMID: 39359526 PMC: 11443999. DOI: 10.18502/jovr.v19i3.9404.


Global tendency and research trends of minimally invasive surgery for glaucoma from 1992 to 2023: A visual bibliometric analysis.

Li R, Liu H, Zhang K, Lu Z, Wang N Heliyon. 2024; 10(16):e36591.

PMID: 39258206 PMC: 11385773. DOI: 10.1016/j.heliyon.2024.e36591.